Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: [Problem] To develop novel therapeutic agents for viral diseases such as coronavirus infections. [Solution] The present invention provides a therapeutic or prophylactic agent for viral diseases containing a compound with inhibitory activity against the function of Pin1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: [Problem] To develop a group of novel compounds with an inhibitory activity against the function of Pin1 so as to use them as candidate compounds for medicaments.

Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A compound represented by the following formula (1) is provided: wherein X represents a sulfur atom or —CH?CH—; A1 to A4 each independently represent a carbon atom or a nitrogen atom, and at least one of A1 to A4 is a nitrogen atom; R1 represents any one of a 1,2,3,4-tetrahydroquinolyl group (or a 3,4-dihydro-1(2H)-quinolyl group), a 3,4-dihydro-4,4-dimethyl-1(2H)-quinolyl group, a 2,3,4,5-tetrahydro-1H-1-benzazepinyl group, or a substituent represented by the following formula (2): wherein R4 represents a 2,3,4-trifluorophenyl group, a 4-iodophenyl group, a 2,3-difluorophenyl group, a 3,5-difluorophenyl group, a 5-fluoro-2-methylphenyl group, a 3-pentafluorosulfanylphenyl group, a 2,6-dimethylphenyl group, a 4-benzyloxyphenyl group, a 3,5-bis(trifluoromethyl)biphenyl group, a 4-tert-butylphenyl group, a 3-methoxyphenyl group, an unsubstituted or substituted pyridyl group, or an unsubstituted or substituted naphthyl group; R5 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a l

Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

Abstract: It is an object of the present invention to provide a compound inhibiting the binding between ALS-related mutant SOD1 and Derlin-1, a medicament comprising the compound, and a method for treating ALS by administering the medicament to a patient.

Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.

Abstract: [Problem] To provide a novel PIM-3 inhibitor and a novel cancer therapeutic drug, in particular, a therapeutic drug for pancreatic cancer. [Solution] A PIM-3 kinase inhibitor comprising a compound represented by general formula (I) or a pharmacologically acceptable salt, hydrate or solvate thereof.

Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

Abstract: [Problem] The present invention addresses the problem of providing a compound that is useful for preventing or treating diseases associated with malfunctioning of PGI2 receptors, in particular, pulmonary hypertension. [Solution] A positive allosteric regulator of a PGI2 receptor which comprises a compound represented by formula (1) or a pharmaceutically acceptable salt, hydrate or solvate thereof. (1) (In the formula, R1 is a branched chain or cyclic alkyl or alkenyl having 3 to 10 carbon atoms which may be substituted, R2 is a hydrogen atom or an alkyl having 1 to 6 carbon atoms which may be substituted, R3 is 1 to 4 substituents which are the same or different independently selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl having 1 to 6 carbon atoms which may be substituted, and an alkoxy having 1 to 6 carbon atoms which may be substituted, and A is an aryl which may be substituted or a heteroaryl which may be substituted.

Abstract: In a method for detecting fluorescence or absorbance of the present invention, a diaphorase causes reduction from resazurin to resorufin in the presence of an SH reagent and NADH or NADPH, and the resulting fluorescence intensity or absorbance is measured. A method for measuring ADP of the present invention includes a 2-1 process in which glucose is reacted with ADP and an ADP-dependent hexokinase, a 2-2 process in which the glucose-6-phosphate obtained in the 2-1 process is reacted with NAD or NADP and glucose-6-phosphate dehydrogenase, and a 2-3 process in which resazurin is reacted with the NADH or NADPH obtained in the 2-2 process and a diaphorase in the presence of an SH reagent, and the resulting fluorescence intensity or absorbance is measured.

Abstract: A compound of formula (I) wherein variables are as defined herein having an autotaxin inhibitory effect and a pharmaceutical composition comprising the same.